276 related articles for article (PubMed ID: 23558524)
21. Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.
Maura F; Cutrona G; Mosca L; Matis S; Lionetti M; Fabris S; Agnelli L; Colombo M; Massucco C; Ferracin M; Zagatti B; Reverberi D; Gentile M; Recchia AG; Bossio S; Rossi D; Gaidano G; Molica S; Cortelezzi A; Di Raimondo F; Negrini M; Tassone P; Morabito F; Ferrarini M; Neri A
Leuk Lymphoma; 2015; 56(11):3150-8. PubMed ID: 25860243
[TBL] [Abstract][Full Text] [Related]
22. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
[TBL] [Abstract][Full Text] [Related]
23. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
24. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
25. IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
Rizzo D; Chauzeix J; Trimoreau F; Woillard JB; Genevieve F; Bouvier A; Labrousse J; Poli C; Guerin E; Dmytruk N; Remenieras L; Feuillard J; Gachard N
Leukemia; 2015 Feb; 29(2):337-45. PubMed ID: 24943833
[TBL] [Abstract][Full Text] [Related]
26. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
27. SF3B1 mutations in chronic lymphocytic leukemia.
Wan Y; Wu CJ
Blood; 2013 Jun; 121(23):4627-34. PubMed ID: 23568491
[TBL] [Abstract][Full Text] [Related]
28. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
[TBL] [Abstract][Full Text] [Related]
29. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
[TBL] [Abstract][Full Text] [Related]
30. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.
Falisi E; Novella E; Visco C; Guercini N; Maura F; Giaretta I; Pomponi F; Nichele I; Finotto S; Montaldi A; Neri A; Rodeghiero F
Hematol Oncol; 2014 Mar; 32(1):22-30. PubMed ID: 23861036
[TBL] [Abstract][Full Text] [Related]
31. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
32. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.
Rigolin GM; del Giudice I; Formigaro L; Saccenti E; Martinelli S; Cavallari M; Lista E; Tammiso E; Volta E; Lupini L; Bassi C; Bardi A; Sofritti O; Daghia G; Cavazzini F; Marinelli M; Tavolaro S; Guarini A; Negrini M; Foà R; Cuneo A
Genes Chromosomes Cancer; 2015 Dec; 54(12):818-26. PubMed ID: 26355802
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
Onaindia A; Gómez S; Piris-Villaespesa M; Martínez-Laperche C; Cereceda L; Montes-Moreno S; Batlle A; de Villambrosia SG; Pollán M; Martín-Acosta P; González-Rincón J; Menarguez J; Alvés J; Rodriguez-Pinilla SM; García JF; Mollejo M; Fraga M; García-Marco JA; Piris MA; Sánchez-Beato M
Haematologica; 2015 May; 100(5):e200-3. PubMed ID: 25552700
[No Abstract] [Full Text] [Related]
34. Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
[TBL] [Abstract][Full Text] [Related]
35. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.
Zent CS; Burack WR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):119-24. PubMed ID: 25696844
[TBL] [Abstract][Full Text] [Related]
36. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
[TBL] [Abstract][Full Text] [Related]
37. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
Jeromin S; Weissmann S; Haferlach C; Dicker F; Bayer K; Grossmann V; Alpermann T; Roller A; Kohlmann A; Haferlach T; Kern W; Schnittger S
Leukemia; 2014 Jan; 28(1):108-17. PubMed ID: 24113472
[TBL] [Abstract][Full Text] [Related]
38. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
39. Recurrent gene mutations in CLL.
Martínez-Trillos A; Quesada V; Villamor N; Puente XS; López-Otín C; Campo E
Adv Exp Med Biol; 2013; 792():87-107. PubMed ID: 24014293
[TBL] [Abstract][Full Text] [Related]
40. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
